Fox Run Management L.L.C. Invests $877,000 in Roivant Sciences Ltd. $ROIV

Fox Run Management L.L.C. bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 57,932 shares of the company’s stock, valued at approximately $877,000.

Other large investors also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. CWM LLC lifted its stake in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the period. Osaic Holdings Inc. boosted its holdings in Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock worth $65,000 after buying an additional 3,882 shares in the last quarter. Finally, Rossby Financial LCC purchased a new stake in Roivant Sciences during the second quarter worth $113,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on ROIV. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Roivant Sciences in a report on Monday, February 9th. The Goldman Sachs Group lifted their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Citigroup raised their price objective on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.69.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $28.49 on Friday. The stock has a market capitalization of $20.39 billion, a P/E ratio of -24.35 and a beta of 1.22. The business has a 50 day simple moving average of $23.80 and a two-hundred day simple moving average of $19.32. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $29.20.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 917,282 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $23.04, for a total value of $21,134,177.28. Following the transaction, the director owned 17,130,445 shares in the company, valued at approximately $394,685,452.80. This trade represents a 5.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Frank Torti sold 1,400,000 shares of Roivant Sciences stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the sale, the insider directly owned 13,736,547 shares in the company, valued at approximately $376,656,118.74. This trade represents a 9.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 13,318,014 shares of company stock worth $315,727,023 in the last quarter. 10.80% of the stock is owned by insiders.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.